Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-02-02

Clinical Trial Update: ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ZIMURA in combination with LUCENTIS for neovascular age-related macular degeneration has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lucentis (ranibizumab)
  • Zimura (ARC1905)

Snippet

Sponsor: Ophthotech Corporation | Conditions: Neovascular Age-related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2022-02-02